Market Overview

Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

Share:
Related BMY
Fast Money Picks For June 30
The Note Moving Pharma Giants Today
Can Hepatitis B Be A Blockbuster Bug? (Investor's Business Daily)
Related MRK
Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint
Barron's Recap: Airline Stocks Ready To Soar
The Vetr community has downgraded $MRK to 4-Stars (Vetr)

Shares of Bristol-Myers Squibb (NYSE: BMY) fall 7.15% following Q4 results and management's announcement that the company will continue Phase 1 studies of nivolimab and Yervoy in lung cancer before advancing to Phase 3.

BMO Capital Markets analyst Alex Arfaei's noted that many investors expected a rapid advancement to stage 3 and this news will disappoint. Arfaei added that Bristol-Myer's management comments may be interpreted as a sign of caution.

The analyst reported that this news is “incrementally positive” for Merck & Co. (NYSE: MRK) who is developing a competing therapy in lung cancer, MK- 3475.

Arfaei rates Bristol-Myers as Market Perform with a $56.00 price target, and Merck as Outperform with a $56.00 price target.

Bristol-Myers is currently down 4.75% at $51.39 and shares of Merck are up 0.87% at $52.05.

Latest Ratings for BMY

DateFirmActionFromTo
Jun 2015Piper JaffrayInitiates Coverage onUnderperform
May 2015BerenbergInitiates Coverage onHold
Apr 2015Deutsche BankMaintainsHold

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Alex Arfaei BMO Capital MarketsAnalyst Color News Analyst Ratings

 

Related Articles (BMY + MRK)

Around the Web, We're Loving...

Get Benzinga's Newsletters